A correction to published research on senolytics—drugs that selectively eliminate senescent cells—clarifies dosing and outcome measures in aged mice infected with influenza. The findings support senolytics as a tool for reducing both acute and chronic inflammatory responses in aged lungs, with direct relevance to infection susceptibility in aging.
Key Points
- Senolytics reduce acute inflammation in aged mouse lungs post-infection
- Chronic lung inflammation also decreased with senescent cell clearance
- Correction addresses dosing protocol and measurement methodology
Longevity Analysis
Senescent cells accumulate with age and drive inflammatory cascades that impair the body's ability to mount effective immune responses while simultaneously amplifying tissue damage during infection. By removing these dysfunctional cells, senolytics appear to restore immune competence and dampen excessive inflammation in aged lungs—addressing a critical vulnerability in aging populations. This positions cell senescence removal as a mechanistic intervention point for improving resilience during respiratory infection, particularly relevant given the disproportionate burden of severe respiratory illness in older adults.
Original published by Wiley Aging Cell.